
Stay informed with the latest company news and developments in Egypt and the region through our unbiased and direct news platform. Our blog publishes press releases and news directly from companies and their PR agencies, giving you a clear and unfiltered view of the industry. Make informed decisions with our easy to follow and clutter-free approach to company news.
11 April, 2021
هانيويل تلتزم بحياد الكربون في عملياتها التشغيلية ومنشآتها بحلول عام 2035
WORLD SECURITY EXPANDS ITS SERVICE OFFERINGS, FUELLING GROWTH
Dubai, United Arab Emirates, 11 April 2021: DP World, UAE Region’s next-generation service provider, World Security hosted key customers and stakeholders on a webinar to educate customers about the services provided by the entity and the numerous advantages of operating in Jebel Ali Free Zone (Jafza). The virtual event was organised following the success of the first webinar that took place last year.
Held on 7 April 2021, the webinar highlighted World Security’s journey since its inception in 1975, with a primary focus on the expansion of a wide range of services including, AYDI Manpower Solutions introduced in 2018 and Soft Services – Facility Management (FM) launched in 2020. Through their newest offerings, World Security will provide cleaning and disinfection services, sterilisation, housekeeping, and other outsourced services.
Maintaining maximum safety and adhering to the guidelines put forth by the local authorities has always been a top priority for the entity. However, taking into account the rapidly increasing demand for cleaning and disinfection services in recent times, the entity has heavily invested in providing top-notch services carried out by well-trained employees, equipped to handle state-of-the-art machinery.
World Security’s portfolio of innovative solutions with remote control capabilities, advanced robotics and surveillance equipment have firmly established its role as Dubai’s leader for security with purpose-built solutions that are integral to safeguard assets as well as the valuable properties of the clients.
Ayoub Al Mulla, Chief Operating Officer of World Security, said: “The world, has, in essence, transformed in many ways since the onset of the global pandemic. People have recognised the importance of having a secure space. Organisations, retail outlets and public spaces are now open to increasing investment for security services. At World Security, we understand this growing concern for safety and are equipped to offer a combination of services, including personnel and technology-enabled solutions to protect our customers’ interests. Our sole aim is to enable the success of our customers and ensure their well-being through our customised manpower solutions. Our services that are compliant with pertinent government regulations and our customer-oriented approach have strengthened our clients’ trust in the optimum solutions we offer.”
Al Mulla added, “Despite the on-going pandemic, we have provided disinfection services for over 15 million sq metres and have successfully carried out disinfection of over 60K vehicles. We have also become a preferred solutions provider for the hospitality sector gaining noteworthy clients.”
Building strong partnerships and collaborations is one of the core values of World Security. This approach has helped the company increase their portfolio of clients that includes leading government and private sector entities. Some of their key customers are Jafza, PCFC, Dubai Customs, Roads and Transport Authority (RTA), Dubai Police, Emaar, Nakheel, Meraas, among others.
Apart from the latest development, the next-generation service provider has been offering an array of solutions including cash and valuables in transit, events security, guarding services, marine security and smart security solutions. It also empowers and trains security personnel through its SIRA accredited World Security Training Institute.
Devmark Group lands exclusive sales & marketing contract to launch Palm View project
Leaders in integrated real estate expertise, is offering strategic advisory for landmark development
Strategy pays off with sales success of private pre-launch broker’s event
Dubai, United Arab Emirates, 11 April 2021: Devmark Group, experts in integrated real estate, has been exclusively appointed to create the marketing strategy and direct the sales for the 263 apartments in the 43-story, Palm View tower in Dubai.
Located just below the trunk of Palm Jumeirah, with a 180 Degree view across to Bluewaters Island, Palm Jumeirah and Burj Al Arab, the fully furnished apartments are situated on the 17th to 43rd floors of the tower with the Avani hotel rooms occupying the lower floors.
“One of the reasons why we were exclusively appointed as a specialist consultancy for this project, was our strategic advisory, which added significant value to the project’s market proposition. We found that the latest global trends suggested residents have become far more spatially and environmentally aware following the lockdown,” said Sean McCauley, CEO, Devmark Group.
“Besides advising about the projects positioning, pricing, facilities and amenities, we wanted to create a live, work and relax concept, that would work equally well indoors as well as outdoors,” added McCauley.
In addition to all of the hotel facilities, Devmark Group went on to create the exclusive Resident’s Club, which will feature private pool access and in-room dining. Other facilities will include an indoor kid’s play area, a wellbeing centre and spa, a fully equipped gym and dance studio, golf simulator, a lounge and library, business centre with dedicated workspaces, housekeeping services, as well as a five-star private concierge.
“The Club also gives residents access to several beach clubs throughout Dubai. We packaged this as an exclusive offer to residents which has proved extremely popular with investors,” said McCauley.
“In fact, during a series of private pre-launch broker events recently, we have now completely sold out our initial allocation of pre-launch units. So, we will now release more units ready for our upcoming public launch,” he added.
The apartments come complete with picture, floor to ceiling windows that take full advantage of the commanding views over the Palm Jumeirah and Dubai Marina, as well as custom furniture, quality fittings and furnishing and Bosch white goods and other branded appliances.
Investors will now have the opportunity to choose from one, two and three-bedroom units with prices starting from AED 1,950,000.
Commenting about the overall development, Devmark Group managing director Richard Aybar, said, “This is a quality development, in a fantastic location, at a competitive price and as such is much sought-after, attracting a lot of attention from the UAE’s real estate brokers and investment community, as we have already witnessed.
“Another major benefit for prospective investors is that the Palm View project is already built and ready to move in, so they don’t need to be concerned about completion dates or the quality of the interior fittings and furnishing.
“There is also a five-year post-handover payment plan so should investors wish to do so, they can lease out their apartments immediately, securing a projected average return of 10% net of service charges over the next five years,” added Aybar.
Investors can also opt to let Avani Hotels, which is part of the renowned Thai-based international hotel group Minor Hotels, manage their property, whereby the apartment is simply pooled with the hotel inventory and offered at market rates to any potential guests.
The Devmark Group is comprised of specialist units including real estate advisory, project sales and marketing, investment and Prop-Tech solutions. Unique in the market, its ecosystem has been designed to create tailor-made solutions across all stages of the real estate project value chain to offer developers the strategy, creativity and insight that every project needs to succeed.
05 April, 2021
الجونة تستضيف النسخة الرابعة من بطولة الجونة الدولية للموتوكروس
CoVIg-19 Plasma Alliance Announces Topline Results from NIH-Sponsored Clinical Trial of Investigational COVID-19 Hyperimmune Globulin Medicine
Phase 3 Inpatient Treatment With Anti-Coronavirus Immunoglobulin (ITAC) Clinical Trial Sponsored and Funded by the National Institute of Allergy and Infectious Diseases (NIAID), Part of the National Institutes of Health (NIH), Did Not Meet Its Endpoints to Show Efficacy in Adults Hospitalized With COVID-19
OSAKA, Japan & KING OF PRUSSIA, Pa.--(BUSINESS WIRE/AETOSWire)-- The CoVIg-19 Plasma Alliance today announced that the Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), did not meet its endpoints. No serious safety signals were raised in the trial.
The study aimed to determine whether an investigational anti-coronavirus hyperimmune intravenous immunoglobulin (H-Ig) medicine (referred to by the Alliance as CoVIg-19) could reduce the risk of disease progression when added to standard of care treatment including remdesivir in hospitalized adult patients at risk for serious complications. Analyses remain ongoing and NIAID and the INSIGHT Network intend to publish the full results of the trial soon.
“While the results of this particular clinical trial are disappointing, we are proud that as an industry we proactively and collaboratively pursued this work, and that the program may contribute to a growing understanding of this challenging virus and strategies for patient care. Since we embarked on this development program, and throughout the pandemic, we have learned much from our scientific research. Importantly, we learned that as an industry we have the fortitude and capability to quickly work together for the greater good of human health,” said Bill Mezzanotte, MD, MPH, Executive Vice President, Head of Research and Development and Chief Medical Officer, CSL Behring and co-leader of the CoVIg-19 Alliance.
“We are especially proud that we pooled resources, brought our plasma expertise and infrastructure together at our own cost to benefit public health and added to our understanding of a complex field. We are extremely thankful to all those who collaborated day and night for one year in testing circumstances to develop and manufacture a potential solution for COVID-19, including those organizations from outside the industry who chose to support us,” said Julie Kim, president of Plasma-Derived Therapies Business Unit, Takeda and co-leader of the CoVIg-19 Alliance. “We express our sincere gratitude to the COVID-19 survivors who generously donated their plasma to make our work possible, the patients who graciously participated in the trial, and to the regulatory and government agencies for their partnership and flexibility to support our efforts.”
Following the outcome of the ITAC trial, the CoVIg-19 Plasma Alliance’s work now concludes. The one-year collaboration involving organizations from across the world has strengthened relationships within and outside the industry, enabled a renewed perspective toward pragmatic regulation based on scientific evidence and need, and provided a well-defined, legally compliant framework for future collaborative opportunities to address urgent public health needs.
About the ITAC Trial
The Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial is a global, multi-center, double-blind, placebo-controlled, randomized trial sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). It was designed to test the safety, tolerability and efficacy of a combination treatment regimen for coronavirus disease 2019 (COVID-19) consisting of the antiviral remdesivir along with an anti-coronavirus hyperimmune intravenous immunoglobulin (H-Ig), which contains a highly concentrated solution of antibodies that neutralize SARS-CoV-2. The antibodies in the H-Ig come from the liquid portion of blood, or plasma, donated by healthy people who have recovered from COVID-19.
Through the NIAID-funded INSIGHT Network, the study team enrolled nearly 600 adult patients at 63 sites in the United States and 10 other countries on five continents. Volunteers were eligible for the trial if they had been hospitalized for COVID-19 and had symptoms for 12 days or fewer without life-threatening organ dysfunction or end-organ failure. Four companies provided investigational H-Ig materials for the trial, including CSL Behring and Takeda on behalf of the CoVIg-19 Plasma Alliance, as well as Emergent BioSolutions and Grifols. Further information about the ITAC trial is available at ClinicalTrials.gov under study identifier NCT04546581.
About the CoVIg-19 Plasma Alliance
In an effort to help fight against the COVID-19 pandemic, the CoVIg-19 Plasma Alliance was formed in April 2020 to help develop a potential plasma-derived therapy for people at risk for serious complications from COVID-19. The Alliance brought together world-leading plasma companies to work on the development of an investigational unbranded polyclonal anti-SARS-CoV-2 hyperimmune globulin medicine intended for the treatment of patients at risk for serious complications from COVID-19. The hyperimmune globulin, known as CoVIg-19, is a high-quality pharmaceutical product that contains purified, consistent and concentrated levels of convalescent antibodies.
Co-founded by CSL Behring and Takeda, the Alliance also included BioPharma Plasma, Biotest, GC Pharma, LFB, National Bioproducts Institute, Octapharma and Sanquin. The Bill & Melinda Gates Foundation provided advisory support. Microsoft provided technology including the Alliance website and the Plasma Bot for donor recruitment. Organizations including Pall and Uber Health also made in-kind contributions to the Alliance.
The Alliance is also part of “The Fight Is In Us” campaign, a coalition seeking to mobilize tens of thousands of people in the United States who have recovered from COVID-19 to donate their blood plasma. Individuals who have recovered from COVID-19, or know someone who has, can visit TheFightIsInUs.org to understand if they may be eligible to donate and find a nearby blood or plasma donor center using a simple self-screening tool.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210402005026/en/